| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Caspase 3
Zerumbone targets multiple pathways involved in cancer, inflammation, and viral infection. It inhibits Sonic hedgehog signaling, a pathway critical for cancer cell proliferation and survival. It induces apoptosis in cancer cell lines. It suppresses the LPS-induced inflammatory response and represses activation of the NLRP3 inflammasome in macrophages. It downregulates COX-2 and iNOS expression via modulation of NF-κB activation. It binds to transgelin (TAGLN) and reduces the retention of USP1 in the cytoplasm and the degradation of ZEB1 ubiquitination. It inhibits Epstein-Barr virus activation with an IC50 of 0.14 mM. |
|---|---|
| ln Vitro |
In vitro, Zerumbone has demonstrated anti-cancer, antioxidant, anti-inflammatory, and anti-proliferative activity. It inhibits Sonic hedgehog signaling and induces apoptosis in cancer cell lines. It suppresses the LPS-induced inflammatory response and represses activation of the NLRP3 inflammasome in macrophages. It potently inhibits the activation of Epstein-Barr virus with an IC50 of 0.14 mM. It downregulates COX-2 and iNOS expression via modulation of NF-κB activation. It binds to transgelin (TAGLN).
|
| ln Vivo |
In vivo, Zerumbone has been studied for its anti-inflammatory and anticancer effects. It suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis. Its anti-inflammatory activity is mediated by downregulating COX-2 and iNOS expression via modulation of NF-κB activation. It has antinociceptive effects. It has been shown to have hepatoprotective effects. However, detailed in vivo efficacy and safety data are described in the primary literature. The compound is intended for research use only.
|
| Enzyme Assay |
For in vitro biochemical assays, Zerumbone is evaluated for its effects on signaling pathways and enzyme activities. Sonic hedgehog signaling inhibition is assessed using reporter gene assays or by measuring Gli transcription factor activity. Apoptosis is assessed by measuring caspase activity and DNA fragmentation. NLRP3 inflammasome activation is assessed by measuring IL-1β and IL-18 secretion. COX-2 and iNOS expression is measured by Western blotting or ELISA. NF-κB activation is assessed by measuring IκB degradation or NF-κB DNA binding. These cell-free and cell-based assays help characterize the compound's multiple biological activities.
|
| Cell Assay |
In vitro cellular assays for Zerumbone are performed using various cell types including cancer cells, macrophages, and virus-infected cells. Cells are cultured in standard media and treated with the compound at various concentrations. Cell viability and proliferation are assessed using MTT or SRB assays. Apoptosis is evaluated by measuring caspase activity and Annexin V/PI staining. Inflammatory responses are induced by LPS treatment, and cytokine production is measured by ELISA. NF-κB activation is assessed by Western blotting. Antiviral activity is assessed using Epstein-Barr virus-infected cell cultures. These cellular assays help validate the compound's anticancer, anti-inflammatory, and antiviral activities.
|
| Animal Protocol |
In vivo animal experiments with Zerumbone are conducted in models of inflammation, cancer, and pain. For anti-inflammatory studies, models of acute or chronic inflammation are used. For anticancer studies, tumor xenograft models are employed. For antinociceptive studies, pain models are used. Zerumbone is administered via oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints include inflammation reduction, tumor growth inhibition, and pain reduction. Tissue samples are analyzed for COX-2, iNOS, and NF-κB markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Zerumbone have been partially characterized. As a sesquiterpene with a molecular weight of 218.34, it is expected to have moderate oral bioavailability and good tissue distribution. The compound is soluble in DMSO (30 mg/mL) and ethanol (25 mg/mL). It is classified as a Dangerous Good for transport. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Zerumbone is not extensively characterized. As a natural sesquiterpene from Zingiber zerumbet, it is generally considered to have a moderate safety profile, but comprehensive toxicity studies are limited. The compound is classified as a Dangerous Good for transport. It is intended for research use only and not for human therapeutic applications. Researchers should follow standard laboratory safety practices when handling Zerumbone.
|
| References |
|
| Additional Infomation |
Zerumbone is a sesquiterpene cyclic ketone with the structure (1E,4E,8E)-α-humulene, where a carbonyl group replaces one of the carbon atoms connecting the two double bonds. It is primarily extracted by steam distillation from turmeric (Zingiber zerumbet Smith), an edible plant mainly found in Southeast Asia. Zerumbone possesses anti-inflammatory, phytometabolic, and glioma-associated oncogene-inhibiting effects. It is a sesquiterpene cyclic ketone derived from the hydrogenation of α-humulene. Zerumbone has been reported to be found in Artemisia annua, Alpinia galanga (Zingiber montanum), and other organisms with relevant data.
Zerumbone is a valuable research tool for studying Sonic hedgehog signaling, inflammation, and cancer. Its inhibition of Sonic hedgehog signaling makes it useful for investigating this pathway in cancer development and for developing new cancer therapies. Its suppression of NLRP3 inflammasome activation provides opportunities for studying inflammation and developing anti-inflammatory agents. Its antiviral activity against Epstein-Barr virus makes it relevant for virology research. Its ability to bind to transgelin and modulate USP1 and ZEB1 provides opportunities for studying protein interactions and ubiquitination. As a component of wild ginger, it is also important for natural product chemistry. |
| Molecular Formula |
C15H22O
|
|---|---|
| Molecular Weight |
218.3346
|
| Exact Mass |
218.167
|
| CAS # |
471-05-6
|
| PubChem CID |
5470187
|
| Appearance |
White to light yellow solid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
321.6±42.0 °C at 760 mmHg
|
| Melting Point |
67-69℃
|
| Flash Point |
133.9±22.8 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.468
|
| LogP |
5.34
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
354
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C([H])([H])[H])=C([H])C([H])([H])C([H])([H])C(C([H])([H])[H])=C([H])C([H])([H])C(C([H])=C1[H])(C([H])([H])[H])C([H])([H])[H] |c:6,19,t:27|
|
| InChi Key |
GIHNTRQPEMKFKO-SKTNYSRSSA-N
|
| InChi Code |
InChI=1S/C15H22O/c1-12-6-5-7-13(2)14(16)9-11-15(3,4)10-8-12/h7-9,11H,5-6,10H2,1-4H3/b11-9+,12-8+,13-7+
|
| Chemical Name |
(2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~572.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (9.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (9.53 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (9.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5802 mL | 22.9011 mL | 45.8022 mL | |
| 5 mM | 0.9160 mL | 4.5802 mL | 9.1604 mL | |
| 10 mM | 0.4580 mL | 2.2901 mL | 4.5802 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
